SCHEMBL1522011

SCHEMBL1522011

Cc1cc(F)c(NC(=O)Nc2cc(C(F)(F)F)no2)cc1N1Cc2cnc(NCCN(C)C)cc2N(C)C1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NEK7 Q8TDX7 2/20 0.35
TNK2 Q07912 5/20 0.35
MAP4K2 Q12851 5/20 0.35
MAPK14 Q16539 3/20 0.35
BRAF P15056 4/20 0.35
KDR P35968 3/20 0.35
KRAS P01116 2/20 0.35
RAF1 P04049 2/20 0.35
MAP2K2 P36507 2/20 0.35
MAP2K1 Q02750 2/20 0.35
EPHX2 P34913 1/20 0.34
IDO1 P14902 3/20 0.33
ABL1 P00519 3/20 0.33
BMX P51813 3/20 0.33
LCK P06239 1/20 0.33
FES P07332 1/20 0.33
RET P07949 1/20 0.33
PDGFRB P09619 1/20 0.33
KIT P10721 1/20 0.33
FGFR1 P11362 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521778 0.88 TNK2 (0.48) TNK2MAP4K2KDRABL1BMX
SCHEMBL1521554 0.83 BRAF (0.48) NEK7MAPK14BRAFKDRKRAS
SCHEMBL1521891 0.82 TNK2 (0.46) TNK2MAP4K2MAPK14BRAFKDR
SCHEMBL1521607 0.82 TNK2 (0.33) TNK2MAP4K2BRAFKDRKRAS
SCHEMBL1521988 0.80 BRAF (0.46) MAPK14BRAFKDRKRASRAF1
SCHEMBL1521665 0.79 ABL1 (0.48) TNK2MAP4K2KDRABL1BMX
SCHEMBL1521411 0.78 FGFR4 (0.35) TNK2MAP4K2KDRABL1BMX
SCHEMBL5061782 0.76 BRAF (0.47) NEK7MAPK14BRAFKDRKRAS
SCHEMBL1521499 0.76 BRAF (0.47) NEK7MAPK14BRAFKDRKRAS
SCHEMBL1521513 0.76 BRAF (0.47) NEK7MAPK14BRAFKDRKRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US claimed
EP-2063896-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US claimed
WO-2008033999-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-03-20 WO claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 NEK7 789/4885TNK2 119/4885MAP4K2 22/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 NEK7 789/4885TNK2 119/4885MAP4K2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.